A Personalized Management of A Chronic Active Tuberculosis Patient, Hsinchu CityDOI: 10.6525/TEB.201910_35(19).0001
Hsuan-Chu Lin1*, Jui-Hsin Chang1, Shu Ya Lu1,2, Fang Shin Wang2, Yu-Ju Chou1, Tzu-Chun Chen1, Jhy-Wen Wu1, Kun-Bin Wu1
2019 Vol.35 NO.19
Correspondence Author： Hsuan-Chu Lin1*
The main treatment regimens of chronic active tuberculosis (CATB) patients are patient-centered supportive services and effective isolation. High-dose isoniazid was once used to reduce the infectivity of CATB patients. Bedaquiline, a new second-line drug for multiple drug-resistant tuberculosis patients, was introduced in 2014as a choice for treating CATB patients in Taiwan. Our patient, diagnosed as CATB in 2010, started to receive bedaquiline since 2015, and completed the treatment in 2017. During this period, he had changed his attitude and cooperated well with public health and medical staffs. Public health staffs implemented a patient-centered, formulated a personalized management plan, kept close contact with medical staffs, and updated with his latest medical conditions. The good trusting relationship facilitated the completion of treatment.